Spain Approves New Medicines Law with Conditional Funding and Dynamic Pricing
Key Questions
What new pathways does Spain's draft Medicines Law introduce?
Spain's Council of Ministers approved a draft Medicines Law introducing a conditional funding pathway for 65-day expedited access and dynamic pricing for generics/biosimilars. This will reshape market access timelines and pricing negotiations.
What happened to the original selected price provision in the law?
The original selected price provision was removed, suggesting industry pushback during the approval process. Spain's Drug Price Confidentiality Law is also nearing official publication.
How will this law impact EU5 market access?
As a concrete EU5 policy development, the law will reshape market access timelines and pricing negotiations in Spain. It represents a significant shift toward conditional funding and flexible pricing models.
Spain's Council of Ministers approved a draft Medicines Law introducing a conditional funding pathway (65-day expedited access) and dynamic pricing for generics/biosimilars. The original selected price provision was removed, suggesting industry pushback. This is a concrete EU5 policy development that will reshape market access timelines and pricing negotiations in Spain.